RU2607594C2 - Комбинация инотузумаба озогамицина и торизела для лечения рака - Google Patents
Комбинация инотузумаба озогамицина и торизела для лечения рака Download PDFInfo
- Publication number
- RU2607594C2 RU2607594C2 RU2014124005A RU2014124005A RU2607594C2 RU 2607594 C2 RU2607594 C2 RU 2607594C2 RU 2014124005 A RU2014124005 A RU 2014124005A RU 2014124005 A RU2014124005 A RU 2014124005A RU 2607594 C2 RU2607594 C2 RU 2607594C2
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- temsirolimus
- treatment
- dose
- inotuzumab ozogamicin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576831P | 2011-12-16 | 2011-12-16 | |
| US61/576,831 | 2011-12-16 | ||
| PCT/IB2012/056958 WO2013088304A1 (en) | 2011-12-16 | 2012-12-04 | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014124005A RU2014124005A (ru) | 2016-02-10 |
| RU2607594C2 true RU2607594C2 (ru) | 2017-01-10 |
Family
ID=47557418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014124005A RU2607594C2 (ru) | 2011-12-16 | 2012-12-04 | Комбинация инотузумаба озогамицина и торизела для лечения рака |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642918B2 (enExample) |
| EP (1) | EP2790723A1 (enExample) |
| JP (1) | JP2013126979A (enExample) |
| KR (2) | KR20140107413A (enExample) |
| CN (1) | CN104023747A (enExample) |
| AU (2) | AU2012351728A1 (enExample) |
| BR (1) | BR112014014181A2 (enExample) |
| CA (1) | CA2859089A1 (enExample) |
| HK (1) | HK1201191A1 (enExample) |
| IL (1) | IL233165A0 (enExample) |
| MX (1) | MX2014007077A (enExample) |
| RU (1) | RU2607594C2 (enExample) |
| WO (1) | WO2013088304A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016119491A (ru) | 2013-11-04 | 2017-12-11 | Пфайзер Инк. | Конъюгаты антитела к efna4 с лекарственным средством |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3307263A4 (en) * | 2015-06-15 | 2019-02-13 | NewSouth Innovations Pty Limited | PHARMACEUTICAL COMBINATIONS OF ORGANO ARSENOXIDE COMPOUNDS AND MTOR HAZARDS |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| CA3066350A1 (en) * | 2017-06-06 | 2018-12-13 | The Johns Hopkins University | Induction of synthetic lethality with epigenetic therapy |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3924372A4 (en) * | 2019-02-13 | 2023-02-22 | Coimmune, Inc. | Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4041299A4 (en) * | 2019-10-10 | 2024-07-31 | Bryologyx Inc. | Method of induction of tumor associated antigens with bryostatin |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124252A2 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4667637A (en) | 1986-01-08 | 1987-05-26 | Brunswick Corporation | Gated knock detector for internal-combustion engines |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| WO2007125252A1 (fr) | 2006-04-26 | 2007-11-08 | France Telecom | Procede et systeme de gestion d'un paiement electronique |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| AU2009313877A1 (en) * | 2008-11-13 | 2011-06-30 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic combination therapies and uses thereof |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| CN107095846A (zh) * | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| JP6042801B2 (ja) * | 2010-04-27 | 2016-12-14 | ロシュ グリクアート アーゲー | ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法 |
-
2012
- 2012-12-04 AU AU2012351728A patent/AU2012351728A1/en not_active Abandoned
- 2012-12-04 RU RU2014124005A patent/RU2607594C2/ru not_active IP Right Cessation
- 2012-12-04 CA CA2859089A patent/CA2859089A1/en not_active Abandoned
- 2012-12-04 EP EP12813985.4A patent/EP2790723A1/en not_active Ceased
- 2012-12-04 WO PCT/IB2012/056958 patent/WO2013088304A1/en not_active Ceased
- 2012-12-04 MX MX2014007077A patent/MX2014007077A/es unknown
- 2012-12-04 CN CN201280062130.7A patent/CN104023747A/zh active Pending
- 2012-12-04 KR KR1020147018997A patent/KR20140107413A/ko not_active Ceased
- 2012-12-04 HK HK15101740.4A patent/HK1201191A1/xx unknown
- 2012-12-04 BR BR112014014181A patent/BR112014014181A2/pt not_active IP Right Cessation
- 2012-12-04 KR KR1020177011120A patent/KR20170049617A/ko not_active Ceased
- 2012-12-04 US US14/365,793 patent/US9642918B2/en not_active Expired - Fee Related
- 2012-12-14 JP JP2012273427A patent/JP2013126979A/ja active Pending
-
2014
- 2014-06-16 IL IL233165A patent/IL233165A0/en unknown
-
2016
- 2016-04-26 AU AU2016202621A patent/AU2016202621B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124252A2 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
Non-Patent Citations (1)
| Title |
|---|
| RABIYA S. TUMA, Enthusiasm for antibody-drug conjugates, JNCI, News, vol.103, issue 20, 19 october, 2011. FASOLO A, Sessa C.Current and future directions in mammalian target of rapamycin inhibitors development. Expert opin Investig Drugs. 2011 Mar;20(3):381-94. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170049617A (ko) | 2017-05-10 |
| CN104023747A (zh) | 2014-09-03 |
| BR112014014181A2 (pt) | 2017-06-13 |
| CA2859089A1 (en) | 2013-06-20 |
| AU2012351728A1 (en) | 2014-06-19 |
| JP2013126979A (ja) | 2013-06-27 |
| AU2016202621B2 (en) | 2017-11-02 |
| MX2014007077A (es) | 2015-03-06 |
| RU2014124005A (ru) | 2016-02-10 |
| KR20140107413A (ko) | 2014-09-04 |
| US20140335109A1 (en) | 2014-11-13 |
| IL233165A0 (en) | 2014-07-31 |
| WO2013088304A1 (en) | 2013-06-20 |
| AU2016202621A1 (en) | 2016-05-26 |
| EP2790723A1 (en) | 2014-10-22 |
| US9642918B2 (en) | 2017-05-09 |
| HK1201191A1 (en) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202621B2 (en) | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer | |
| US20210030759A1 (en) | Method for treating cancer using hsp90 inhibitors | |
| US20200069694A1 (en) | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 | |
| RU2717570C2 (ru) | Синергистические комбинации ауристана | |
| CA3146422C (en) | COMBINATIONS OF ANTI-HER2-DRUG ANTIBODY CONJUGATIONS AND CHEMOTHERAPY AGENTS, AND METHODS OF USE | |
| RU2769700C2 (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| IL299368A (en) | A combination of an antibody-drug conjugate and an ATR inhibitor | |
| JP2020172487A (ja) | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 | |
| US8883737B2 (en) | Methods of treating cancer | |
| CN114302745A (zh) | 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法 | |
| US20160303232A1 (en) | Combination treatments with seribantumab | |
| EP2570127A1 (en) | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors | |
| CN114302746A (zh) | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 | |
| EP2717912A1 (en) | Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer | |
| Swami et al. | Marine sponge derived eribulin in preclinical and clinical studies for cancer | |
| WO2023039568A1 (en) | Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors | |
| EA049478B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и ингибитора atr | |
| HK1242995A1 (en) | Synergistic auristatin combinations | |
| OA16757A (en) | Compositions and methods for treating cancer using P13K beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors. | |
| AU2013204338A1 (en) | Methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181205 |